For the past three years, the Gamalea Center’s vaccine has been undergoing preclinical studies that have proven the drug’s safety. Animal tests were also successful, and the vaccine suppresses tumor development. It is noted that the drug should teach the body’s immune system to recognize and destroy cancer cells.

The drug is intended for the treatment of adult patients with inoperable or metastatic melanoma, according to TASS.